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Abstract   
Background and objectives: Clinical decision support systems (CDSSs) may help clinicians 
prescribe opioids for chronic non-cancer pain (CNCP) more appropriately. This scoping review 
determined the extent and range of the current evidence on CDSSs for opioid prescribing for 
CNCP in primary care, and whether investigators followed best evidence and current guidance in 
designing, implementing and evaluating these complex interventions. 
Methods: We searched nine electronic databases and other data sources for studies from January 
1st 2008 to October 11th 2019. Two reviewers independently screened the citations. One 
reviewer extracted data and a second verified for accuracy. Inclusion criteria: study of a CDSS 
for opioid prescribing for CNCP in a primary care clinical setting. We reported quantitative 
results in tables and qualitative results in narrative form.  
Results:  Our search yielded 5068 records of which 14 studies met our inclusion criteria. All 
studies were conducted in the United States.  Six studies examined local (eg, health centre) 
CDSSs and eight examined prescription drug monitoring program (PDMP) CDSSs. Three 
CDSSs incorporated evidence-based components. Study aims were heterogeneous and study 
designs included both quantitative and qualitative methodologies. No studies assessed patient 
health outcomes. Few studies appeared to be following guidance for evaluating complex 
interventions.  
Conclusions: Few studies have rigourously assessed the use of CDSSs for opioid prescribing for 
CNCP in primary care settings. Going forward, investigators should include evidence-based 
components into the design of CDSSs and follow guidance for the development and evaluation 



















A Scoping Review on Clinical Decision Support Systems for Opioid Prescribing for  
Chronic Non-Cancer Pain in Primary Care Settings 
 
  
Manuscript Click here to access/download;Manuscript &
References;SPITHOFF Body of Manuscript Scoping Study Feb
2 
 
Abstract   1 
Background and objectives: Clinical decision support systems (CDSSs) may help clinicians 2 
prescribe opioids for chronic non-cancer pain (CNCP) more appropriately. This scoping review 3 
determined the extent and range of the current evidence on CDSSs for opioid prescribing for 4 
CNCP in primary care, and whether investigators followed best evidence and current guidance in 5 
designing, implementing and evaluating these complex interventions. 6 
Methods: We searched nine electronic databases and other data sources for studies from January 7 
1st 2008 to October 11th 2019. Two reviewers independently screened the citations. One 8 
reviewer extracted data and a second verified for accuracy. Inclusion criteria: study of a CDSS 9 
for opioid prescribing for CNCP in a primary care clinical setting. We reported quantitative 10 
results in tables and qualitative results in narrative form.  11 
Results:  Our search yielded 5068 records of which 14 studies met our inclusion criteria. All 12 
studies were conducted in the United States.  Six studies examined local (eg, health centre) 13 
CDSSs and eight examined prescription drug monitoring program (PDMP) CDSSs. Three 14 
CDSSs incorporated evidence-based components. Study aims were heterogeneous and study 15 
designs included both quantitative and qualitative methodologies. No studies assessed patient 16 
health outcomes. Few studies appeared to be following guidance for evaluating complex 17 
interventions.  18 
Conclusions: Few studies have rigourously assessed the use of CDSSs for opioid prescribing for 19 
CNCP in primary care settings. Going forward, investigators should include evidence-based 20 
components into the design of CDSSs and follow guidance for the development and evaluation 21 




Introduction  24 
Two countries at the epicentre of the opioid crisis, Canada and the US, (1–4) recently released 25 
clinical practice guidelines for opioid prescribing for chronic non-cancer pain (CNCP)  (5,6). 26 
These guidelines recommend against using opioid analgesics for CNCP because the harms 27 
frequently outweigh benefits (7–10). When opioids are prescribed for CNCP, the guidelines 28 
recommend risk mitigation strategies and opioid dose tapering. Both guidelines target primary 29 
care providers (PCPs), since they write about half of all opioid analgesic prescriptions in North 30 
America (11–13).  However, evidence shows that PCPs may have difficulty adopting 31 
recommended clinical practices (14–21). Clinical decision support may provide assistance.  32 
 33 
Clinical decision support systems (CDSSs) are electronic systems that assist health care 34 
providers in clinical decision-making, by providing patient-specific data at the point-of-care (14–35 
16). Studies show that CDSSs lead to improvements in clinician performance (a care process 36 
measure), such as ordering appropriate tests and safer prescribing (17–25). Some CDSS design 37 
components are evidence-based, including; requiring a reason for an over-ride; activating 38 
automatically (i.e., the CDSS runs without requiring provider initiation); integrating into the 39 
electronic medical record (EMR); and providing advice to patients (e.g. written materials), as 40 
well as clinicians (14,20,26–28). These components lead to improvements in care process 41 
outcomes. Studies in which the CDSS evaluators are also the developers tend to show positive 42 
impact on process outcomes (26,27). 43 
 44 
However, the impact of CDSS on important patient health outcomes or population health 45 
outcomes is unclear (17–20), and widespread adoption is often limited by implementation issues 46 
(29–34). Additionally, CDSSs can be difficult to develop and evaluate because they are complex 47 
interventions that seek to change the functioning of a complex adaptive system such as a primary 48 
care clinic (35). Therefore, the Medical Research Council in the United Kingdom (UK) 49 
recommends that researchers design and evaluate these interventions through a carefully staged 50 
series of studies targeting key uncertainties as well as a definitive evaluation (35,36). All steps 51 
should include process evaluations and assess for unintended consequences (37).  52 
CDSSs can have a variety of roles in improving adherence to opioid prescribing guidelines for 53 
CNCP. They can be used to reduce the number of new opioid prescriptions for acute pain (38) 54 
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and to reduce the initiation of opioid prescribing for CNCP. They can also be used to improve 55 
prescribing and other measures like risk mitigation strategies for patients already receiving 56 
opioids for CNCP. This is the most challenging role for a CDSS these patients are at high risk of 57 
harms and changing prescribing is very difficult (39,40).  58 
Several studies have evaluated CDSSs for opioid prescribing for CNCP in primary care settings 59 
(41–44). These studies report that the use of a CDSS led to a reduction in opioid prescribing or 60 
improved adherence to clinical practice guidelines (41–44). Several studies have also evaluated 61 
prescription drug monitoring program (PDMP) CDSSs for opioid prescribing for CNCP in 62 
primary care settings. PDMP CDSSs are large, centralized, government-run databases that 63 
prescribers can provide point-of-care for information on a patient’s opioid prescriptions (45,46). 64 
While one PDMP CDSS study found that physicians wrote fewer opioid prescription in 61% of 65 
cases, (47); another study reported no association between PDMP implementation status and 66 
requirement levels (from no requirements to a mandatory requirement to check the PDMP before 67 
prescribing) and physicians’ opioid prescribing for CNCP (48). Four other PDMP CDSS studies 68 
examined PCPs’ use of, and views on PDMPs (49–52).  To date, however, the literature in this 69 
emerging field has not been systematically summarized and analyzed so the benefits and risks of 70 
implementing a CDSS are unclear. 71 
 72 
This scoping review determined the extent and range of the current evidence on CDSSs for 73 
opioid prescribing for CNCP in primary care. Our secondary aim was to determine whether 74 
researchers followed best evidence for the design of the CDSSs and current guidance for the 75 
evaluation of complex interventions. 76 
 77 
Methods  78 
We conducted a scoping review using the frameworks (53,54) described by Colquhoun et al (55), 79 
and the methods outlined by The Joanna Briggs Institute (56). We followed the reporting 80 
guidelines from the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-81 
Analyses) Extension for Scoping reviews (PRISMA-ScR) (57). We created an a priori protocol 82 
and used an iterative approach. Modifications included a secondary research aim and a change to 83 




Study eligibility: We included peer- and non-peer reviewed studies that used quantitative, 86 
qualitative and mixed-methods methodologies. We excluded non-systematic reviews, letters, 87 
opinion articles, analysis articles, clinical practice guidelines and policy documents. We included 88 
all studies where the population was PCPs (ie, family physicians, emergency medicine 89 
physicians, nurse practitioners (NPs) and primary care internists) working in a primary care 90 
setting. Studies that reported less than 50% PCPs or did not report the percentage of PCPs were 91 
excluded unless results were reported by subgroup. We included all studies that assessed a CDSS 92 
that sought to improve to improve opioid prescribing for CNCP patients in a primary care 93 
clinical setting. We excluded studies where primary care providers were working in a secondary 94 
and tertiary settings such as a pain clinic or addiction clinic. We excluded primary care pediatric 95 
clinics. We defined a CDSS as an electronic system that assisted health care providers in clinical 96 
decision-making, by providing patient-specific data at the point-of-care (14–16). We included 97 
studies where the CDSS was integrated into the EMR, or functioned independently (eg, web-98 
accessed), or was embedded within a larger intervention. We excluded studies where CDSS use 99 
was not specified, where it was used for another reason, or where it was not implemented in 100 
clinical settings.  101 
 102 
Data sources and searches  103 
We searched electronic databases (MEDLINE (via OVID), EMBASE, CINAHL, CENTRAL, 104 
PsycINFO and International Pharmaceutical Abstracts (via OVIDSP)) from January 1st 2008 – 105 
October 11 2019. CDSSs developed prior to this period likely evolved or became obsolete (59). 106 
We built a comprehensive search strategy, including the terms “opioid,” and “clinical decision 107 
support systems.”  Since studies used a large number of different keywords and medical subject 108 
headings (MeSH) for a CDSS, we had to conduct a broad search using a large variety of terms, 109 
including; computer systems, health informatics, clinical decision making (Appendix 1 Medline 110 
search strategy). The Medline strategy (Appendix 1) was adapted for the other databases. We 111 
used the Canadian Agency for Drugs and Technologies (CADTH) approach to our grey literature 112 
search (Appendix 2 Grey literature search) (60). We also searched trial registries 113 
(ClinicalTrials.gov, World Health Organization International Clinical Trials Registry Platform 114 
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(WHO ICTRP)), checked reference lists of additional eligible studies and contacted experts (ie, 115 
lead authors on included studies, registered protocols and systematic reviews of CDSSs). 116 
 117 
Screening and selection 118 
Two researchers independently screened abstracts to determine if they met inclusion criteria. 119 
Two researchers then independently screened the full-text of all relevant articles. For both steps, 120 
after we screened 10 to 15 titles and articles, we checked inter-reviewer agreement to ensure it 121 
was least 80% before continuing further. When there were disagreements, a third researcher 122 
(MAO) assisted in making the final decision. We contacted authors for more information when 123 
full text was not available online (58).  124 
 125 
Data extraction  126 
We created and pilot-tested a data extraction form to record the following items: study 127 
population and setting, description of the intervention and implementation process, type of 128 
CDSS, inclusion of evidence-based CDSS components (components that the literature has 129 
consistently found to have an impact on outcomes: requiring a reason for an over-ride; activating 130 
automatically; integrating into the electronic medical record (EMR); and providing advice to 131 
patients and clinicians (14,20,26–28), study aims, methodology and design, study outcomes, 132 
funding information, conflicts of interest, and adherence to guidance for complex interventions 133 
(eg, study was part of a stepped approach to development and evaluation; assessment for 134 
unintended consequences; planned process evaluation; process and outcome measures; 135 
theoretical approach to guide implementation and/or evaluation). One reviewer extracted data 136 
and another researcher reviewed their work (SMS, MAO, QG, SM, SH). This was a modification 137 
from our protocol that specified that two researchers would independently extract the data.  138 
 139 
Data synthesis 140 
We used a flow diagram to report on study selection. We reported quantitative data in tabular 141 
format. We wrote narrative summaries using contextual and process-oriented data. We did not 142 
conduct a detailed assessment of study quality, assess for reporting bias, or risk of bias consistent 143 





Results  147 
Our literature search identified 5068 citations from which 14 were included in the scoping 148 
review (Figure 1). Six studies examined local CDSSs (e.g., specific health system, centre or 149 
clinic) (41,43,44,61–63) while eight examined state-run, web-based, central PDMP CDSSs 150 
(47,49–52,64–66) Results using these two typologies are summarized in Table 1.  Study 151 
descriptions are detailed in Appendix 3.  152 
 153 
 154 
CDSS description  155 
Types of CDSSs included protocols (i.e., forms that guide clinical management) in the EMR, 156 
intranet dashboards, EMR alerts, data repositories and web-based clinical tools. Four local 157 
CDSSs were integrated into the EMR (43,44,62) and two automatically activated (44,62). The 158 
other two required the PCP to activate the CDSS. Studies assessing PDMP CDSSs did not report 159 
any evidence-based design components. 160 
 161 
Study characteristics 162 
All studies occurred in the US and practice settings were mostly primary care clinics. Three were 163 
set in the emergency department (44,47,49). All of the local CDSSs, and three of the PDMP 164 
CDSS studies (47,64,66) were designed to assess whether a CDSS alone or incorporated into a 165 
multi-faceted intervention improved prescribing or adherence to guidelines. The remaining 166 
PDMP CDSS studies determined providers’ behaviour, knowledge of, attitudes toward and use 167 
of CDSSs. Local CDSS study designs included four pre-post interventions, a cluster RCT and a 168 
mixed-methods evaluation. The eight PDMP CDSS studies included a wide variety of study 169 
designs including: three pre-post interventions, a cross-sectional survey, two qualitative, one 170 
mixed methods and one retrospective cohort. Study aims and designs are summarized in Table 2 171 
and described in detail in Appendix 3. One study was part of a stepped approach in evaluating a 172 
complex intervention (63). About half of the studies that assessed the impact of an intervention 173 
included a process evaluation (measures assessing if program components had been implemented 174 
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as intended) (41,43,47,49,62–64).  Two studies reported using a theoretical approach in 175 
implementation and evaluation processes (61,63). 176 
 177 
Implementation processes 178 
All of the studies on local CDSSs described their implementation process, but provided little 179 
detail. None of the PDMP CDSS studies described implementation processes. 180 
 181 
Study Findings 182 
Local CDSSs 183 
Anderson et al. found that the CDSS and summary reports improved compliance with guidelines 184 
(41); Canada et al. reported that a CDSS plus monetary incentives improved adherence to 185 
guidelines (43); Downes et al. found that a CDSS and electronic reports reduced opioid 186 
prescribing and increased urine drug testing and use of pain contracts (62); Gugelmann et al. 187 
found that the CDSS reduced opioid prescribing (44);  Liebschutz et al. reported that a multi-188 
faceted intervention that included a CDSS in both study arms also reduced opioid prescribing 189 
(61); and Seal et al. found in a multi-component intervention (with CDSS in both arms) that 190 
providers “abandoned use” of the CDSS (63).  191 
 192 
PDMP CDSSs 193 
Baehren et al. found that physicians who used PDMP data wrote fewer opioid prescriptions in 194 
61% of cases and more opioid prescriptions in 39% of cases (47); Binswanger et al. found that a 195 
multi-component intervention improved adherence to guidelines (64); Chaudhary et al. found 196 
that most PCPs reported always checking the PDMP before prescribing opioids to new patients 197 
(52). Click et al. found that providers have positive views about PDMPs, but reported barriers in 198 
using them (50). Coleman et al. found that in five of seven records of patient prescribed opioids, 199 
providers accessed the PDMP (51).   Freeman et al. reported that PDMPs are key tools for PCPs 200 
and that barriers include a lack of integration (65); Kohlbeck et al. reported that an educational 201 
intervention increased providers’ knowledge of, behaviour and attitudes toward PDMP CDSSs 202 
(49); Patchett et al. reported that a multi-component intervention increased use of a PDMP and 203 





Funding and conflict of interest 207 
All but two local CDSS studies reported on funding for CDSS evaluation (44,62);  and three 208 
others were missing information on funding for CDSS development (44,63). All PDMP studies 209 
except one (66) provided information on funding for evaluation, but none provided information 210 
on funding for developmentFor all six local CDSS studies, the developers were also the 211 
evaluators or the relationship was unclear or not stated. No evaluators of PDMPs provided 212 
information on their relationship to the PDMP developer (Table 3).  213 
 214 
 215 
Discussion  216 
We identified 14 studies published between 2009 and 2019 that examined CDSSs for opioid 217 
prescribing for CNCP in primary care clinical settings. Six of the studies examined local CDSSs 218 
(that were used locally within a specific health centre, health system or clinic) and eight 219 
examined PDMP CDSSs. Studies evaluating CDSS impact found that the CDSS (alone or more 220 
commonly, part of a dual or multi-component intervention) led to more appropriate prescribing 221 
practices and/or adherence to guidelines. Several PDMP CDSS studies assessed providers’ views 222 
on, and/or their use of PDMP CDSSs. These studies reported frequent use of the PDMP CDSS 223 
and positive views towards the CDSS with some acknowledgement of the barriers and 224 
limitations. These findings are similar to a recent qualitative rapid review that asked providers 225 
about the use of PDMPs (67). No study, however, contained an assessment of patient health 226 
outcomes or assessed for unintended consequences. Additionally, in four studies the evaluators 227 
were also the CDSS developers, a potentially useful situation but one that presents a potential 228 
conflict of interest (26,27), that was not addressed by the investigators. We also found that few 229 
CDSSs included evidence-based components and that in only one study investigators reported 230 
following current guidance for development and evaluation of complex interventions (35,36). 231 
 232 
Our finding that there were only 14 studies, and only one RCT, which met our inclusion criteria 233 
is surprising. In contrast, a 2015 systematic review found seven RCT studies of CDSSs for 234 
antiobiotic prescribing by primary care providers (28). There may be several contributing factors. 235 
The prescription opioid crisis only gained widespread attention in the last decade (68), and it 236 
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takes time to develop a complex intervention like a CDSS (36). It is also possible that some 237 
CDSSs failed to show promise early on and development was subsequently stalled or halted.  238 
Accordingly, there are a number of reports on the development of a CDSSs for opioid 239 
prescribing for CNCP where clinical outcomes have not been reported yet (69–72). And finally, 240 
it is possible that CDSSs are being used without an evaluation plan, as has occurred with many 241 
PDMP CDSSs (73). This may be because of a demand for immediate solutions to the opioid 242 
crisis and an evaluation of a CDSS takes significant time and money.  However, since CDSSs 243 
frequently do not improve patient outcomes (17–20), and may lead to unintended consequences, 244 
a comprehensive evalution is essential (74).  245 
 246 
Most studies in our review that assessed the impact of the CDSS reported an improvement in 247 
prescribing or better adherence to clinical practice guidelines. This aligns with previous research 248 
in other fields: CDSSs have a modest impact on clinican performance (a care process outcome) 249 
(17–25). However, these results need careful interpretation. Most studies were pre-post, non-250 
randomized control or observational designs.  Although—consistent with guidance for scoping 251 
reviews (55,56)—we did not conduct a quality assessment; these types of study designs have 252 
greater threats to validity (75). Additionally, in most of the studies, the CDSS was part of a larger 253 
intervention, so its specific impact was unclear. Another reason for caution is that no studies 254 
assessed patient health outcomes, such as quality of life, morbidity and mortality (76–78). 255 
Reductions in opioid prescribing and better adherence to guidelines may have unintended 256 
consequences (36). For example, studies report that patients often turn to illicit sources of 257 
opioids when they have reduced access to prescribed opioids, increasing their risk of overdose 258 
(79–84). Several studies in a systematic review found that heroin overdoses increased after a 259 
PDMP CDSS was implemented (74). A more recent systematic review, however, found no 260 
consistent association between population-level opioid-related harms (including heroin use and 261 
overdoses) and PDMP CDSSs (85). We also noted a conflict of interest in some studies where 262 
the developers were also the evaluators. Systematic reviews in other fields have demonstrated 263 
that when the CDSS evaluator is also the developer, outcomes are better (26,27). It is possible 264 
that developers achieve better outcomes because they design effective implementation plans 265 
(26), but it is possible that the conflict of interest leads to conscious or unconscious bias (26,86–266 
92). Interestingly, none of the studies reported funding from or involvement of for-profit entities. 267 
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It is possible that CDSSs developed by for-profit entities are not undergoing a publicly-reported 268 
evaluation. This is problematic, and as a recent criminal case demonstrated, can lead to potential 269 
harm to patients (93).  270 
 271 
We found that few of the CDSSs incorporated evidence-based design components. In only one 272 
study did researchers follow guidance for designing and evaluating complex interventions. 273 
Developers may not have incorporated evidence-based components because of the lag time 274 
between development and evaluation: when the CDSS was created the developers may not have 275 
had access to systematic reviews on the various components.  The developer may also feel that 276 
the evidence does not apply to this particular subspecialty or setting (94). Another reason may be 277 
a general excitement and overconfidence in e-health technologies (95). Funders and developers 278 
may be too eager to solve the problem of unsafe opioid prescribing using e-health technologies 279 
and are not ensuring that developers are building on information from the medical literature (95). 280 
Changes are occurring. Between 2012 and 2016, the Substance Abuse and Mental Health 281 
Services Administration (SAMHSA) funded nine projects to integrate PDMP data into EMRs 282 
(96). Investigators might not follow guidance for complex evaluations because it is a lengthy and 283 
expensive iterative process prior to a definitive evaluation (35–37,97).  This is a widespread 284 
issue—few complex interventions appear to undergo modelling, pilot and feasibility testing (98), 285 
and many lack process evaluations (99,100). This is problematic. If researchers conduct a trial 286 
without testing components, possible causal pathways, uncertainties, contextual factors, and 287 
implementation approaches, they risk wasting resources on an expensive trial and perhaps 288 
causing harm (35,37,101). Conversely, if the evaluation takes too long, the technology could 289 
become obsolete before it gains widespread uptake (59). Adopting rapid, concurrent and iterative 290 
pilot and feasibility studies may be the best approach (102–104).  291 
 292 
Limitations 293 
There are two main limitations in our review. In the grey literature search we may have missed 294 
non-English language studies, as we conducted the searches only in English. Second, several of 295 
the studies included both PCPs and other provider types (we excluded those with less than 50% 296 
PCPs), and, as these studies only reported aggregate outcomes, they may not accurately reflect 297 




Conclusion and next steps 300 
Our review reveals that few studies have rigourously assessed the use of CDSSs in the context of 301 
opioid prescribing for CNPP in the primary care setting. More high quality studies are needed. 302 
Going forward, investigators should include evidence-based components into the design of 303 
CDSSs and follow guidance for the development and evaluation of complex interventions, 304 
including pilot studies, process evaluations and an assessment for unintended consequences.  305 
 306 
 307 
  308 
 309 
  310 
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Table 1. Study setting, participants, clinical decision support system (CDSS) type and 
inclusion of evidence-based components  
 






    
Country United States 
  
6/6 (100%) 8/8 (100%) 
Practice 
settings  
Primary care clinic 





























Integrated into EMR 
Automatically activates 
Requires a reason for over-ride 






0/5 (0%) *** 
0/5 (0%) *** 
0/5 (0%) *** 
0/5 (0%) *** 
Table 1 Click here to access/download;Table;Table 1 Scoping Review
CDSSs SPITHOFF Feb 18.docx
Abbreviations: CDSS = Clinical Decision Support System; EMR = electronic medical record; 
N/A = Not Applicable; NP = nurse practitioners; PDMP = Prescription Drug Monitoring 
Program; PCPs = primary care providers;  
*Local CDSSs are used locally within a specific health centre, health system or clinic 
**PDMP CDSSs are large, centralized, government-run databases  
***We excluded 3 studies because they included multiple PDMP CDSSs, and did not provide 
information on a specific CDSS (45,47,49) 




Table 2. Aims and designs of included studies 
 
Aims Design Local 
CDSS* 




To determine if a multi-faceted intervention 
improved prescribing/guideline adherence 
 
 Cluster RCT***  





To detemine if a CDSS improved 
prescribing/guideline adherence  
 Pre-post 
 
0/6 (0%) 1/8 (13%) 














To determine if an intervention affected 
provider knowledge, behaviour, attitudes 








To learn about factors affecting opioid 
prescribing for CNCP, including use of CDSS 
 
 Qualitative 0/6 (0%) 2/8 (25%) 
To pilot a multi-component intervention, 
including a CDSS 
 Mixed-methods 1/6 (17%) 0/8 (0%) 
Table 2 Click here to access/download;Table;Table 2 Scoping Review
CDSSs SPITHOFF Feb 18.docx
Abbreviations: CDSS = Clinical Decision Support System; CNCP = chronic non-cancer pain; 
N/A = Not Applicable; PDMP = Prescription Drug Monitoring Program; RCT = Randomized 
controlled trial  
*Local CDSSs are used locally within a specific health centre, health system or clinic 
**PDMP CDSSs are large, centralized, government-run databases  
***CDSS included in both study arms 
 
Table 3. Funding and relationship between developers and evaluators 






Funding for CDSS 
development  
Public/Non-profit    
Industry  
Not sponsored  









Funding for evaluation Public/non-profit    
Industry  
Not sponsored  








1/8 (13%)  
Relationship between 
developers and evaluators 
Same person, group or organization    
Different person, group or 
organization 









Abbreviations: CDSS = Clinical Decision Support System; PDMP = Prescription Drug 
Monitoring Program  
*Local CDSSs are used locally within a specific health centre, health system or clinic 
**PDMP CDSSs are large, centralized, government-run databases  
 
Table 3 Click here to access/download;Table;Table 3 Scoping Review
CDSSs SPITHOFF Feb 18.docx
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-
Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097 
 
For more information, visit www.prisma-statement.org. 
 
PRISMA 2009 Flow Diagram 
 
Records identified through 
database searching 



























Additional records identified 
through other sources 
(n = 88) 
Records  
(n = 10575) 
Records screened 
(n = 5068) 
Records irrelevant 
(n = 4693) 
Full-text articles assessed 
for eligibility 
(n =375) 
Full-text articles excluded, 
with reasons 
(n = 361) 
 74 not a study 
 184 CDSS not used for 
opioid prescribing for 
chronic non-cancer 
pain (CNCP) in a 
clinical setting   
 74 not a primary care 
population 
 10 duplicates 





Studies included in 
scoping review 
(n = 14) 
Duplicates removed  
(n = 5507) 
Figure Click here to access/download;Figure;19-0199_Figure.doc
